Alexandra Goodman

Dr. Alexandra Goodman

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2021 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
AGAlexandra Goodman
Alexandra Goodman
MBMusa Bilal
Musa Bilal
SAShivantha Amarnath
Shivantha Amarnath
TGTeresa Gentile
Teresa Gentile
ZSZachary Shepherd
Zachary Shepherd
Babesiosis is increasing in the elderly due to an age‐related decline in immunity. Prompt diagnosis with blood smear and PCR prevent life‐threatening complications, like DIC and HLH. Studies focusing on pathophysiology and risk factors are needed.

10 January 2020 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
PKPujitha Kudaravalli
Pujitha Kudaravalli
SSSheikh A. Saleem
Sheikh A. Saleem
AGAlexandra Goodman
Alexandra Goodman
VPVenkata Satish Pendela
Venkata Satish Pendela
MAMuhammad Osman Arif
Muhammad Osman Arif
Biliary-enteric fistula is a rare complication of cholelithiasis that can lead to gallstone ileus. Gallstone impaction in the duodenum and pylorus is extremely rare and can lead to gastric outlet obstruction, a condition known as Bouveret syndrome. Bouveret syndrome needs to be diagnosed and managed in a timely fashion, as it has a high mortality rate. We describe a case of an elderly patient who presented with Bouveret syndrome secondary to impaction of the biliary calculus in the first part of duodenum.

2 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
OBOsama Batayneh
Osama Batayneh
MMMahmoudreza Moein
Mahmoudreza Moein
NNNour Sabiha Naji
Nour Sabiha Naji
APAnsy Patel
Ansy Patel
AMAnupa R. Mandava
Anupa R. Mandava
KGKrishna B. Ghimire
Krishna B. Ghimire
Background: The KMT2A (MLL1) gene is altered in a variety of hematological malignancies and solid tumors. KMT2A-rearranged (KMT2Ar) AML represents a distinct subtype associated with poor outcomes and high relapse rate despite initial responsiveness to chemotherapy. Methods: A total of 3863 cases of AML peripheral blood samples were analyzed using the FoundationOne Heme combined comprehensive hybrid capture-based DNA and RNA sequencing assay. Results: Of the 3863 AML cases, 521 (13.4%) featured genomic alterations (GAs) in the KMT2A gene, 99.1% of which were large rearrangements (KMT2Ar). A total of 56.9% were males with a median age of 62 years. Of the KMT2Ar cases, there were 43.1% KMT2A duplications, 52.7% fusions, and 4.2% not otherwise specified rearrangements. A total of 0.9% of the KMT2A-altered AML cases were short variant mutations. There were no KMT2A (0%) amplifications or deletions. KMT2Ar cases were associated with increased GA frequencies in FLT3 (27.3% vs. 19.8%; p = 0.0002), KRAS (17.2% vs. 7.8%; p < 0.0001) (overall; 1.1% KRAS G12C), and IDH2 (16.0% vs. 10.4%; p < 0.0001), while KMT2A wild-type AML (KMT2Awt) had significantly increased GA frequencies in RUNX1 (20.7% vs. 15.8%; p = 0.0081), ASXL1 (16.6% vs. 10.5%; p = 0.0003), and TET2 (16.4% vs. 10.1%; p = 0.0002), NPM1 (17.5% vs. 0.2%; p < 0.0001), and TP53 (17.8% vs. 7.9%; p < 0.0001). Conclusions: KMT2A rearrangements are common in AML (13.4% of cases featured KMT2Ar). A total of 99.1% of alterations in KMT2A are large rearrangements, with fusions being the most commonly observed alteration (52.7% of total rearrangements). No amplifications or deletions were seen. This genomic landscape study highlights significant genomic differences between KMT2Ar and KMT2Awt AML patients, which may enrich our understanding of the molecular profile and clusters of mutations in AML.

20 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
OBOsama Batayneh
Osama Batayneh
MMMahmoudreza Moein
Mahmoudreza Moein
AGAlexandra Goodman
Alexandra Goodman
DDDevashish Desai
Devashish Desai
DPDean Pavlick
Dean Pavlick
KGKrishna Bilas Ghimire
Krishna Bilas Ghimire
Background/Objectives: This study investigates genomic alterations (GA) between NPM1-mutated (NPM1mut) and wild-type (NPM1wt) acute myeloid leukemia (AML), aiming to better understand the AML genomic profile. NPM1mut AML represents a distinct clinical AML subtype with high relapse rates despite initial responsiveness to chemotherapy. Methods: A total of 4206 AML cases from 2019 to 2024 were analyzed using the FoundationOne Heme assay, incorporating comprehensive DNA and RNA sequencing. Patients were stratified into NPM1mut and NPM1wt cohorts, and genomic differences were systematically compared between the two groups. Results: Among 4206 cases, 633 (15.1%) featured NPM1 GA, with over 99% exhibiting short variant mutations. NPM1mut AML was more common in females (53.4% vs. 41.5%) and associated with a slightly higher median age (62 vs. 60 years). GA was more frequent in NPM1mut AML compared to the NPM1wt and included DNMT3A (39.2% vs. 12.6%; p < 0.0001), PTPN11 (18.3% vs. 7.5%; p < 0.0001), FLT3 (54.5% vs. 14.7%; p < 0.0001), IDH1 (16.1% vs. 5.6%; p < 0.0001), IDH2 (19.0% vs. 9.0%; p < 0.0001), TET2 (23.4% vs. 13.5%; p < 0.0001), and WT1 (12.5% vs. 9.4%; p = 0.02). GA was more frequent in NPM1wt AML and included ASXL1 (17.1% vs. 3.6%; p 0.0001), BCOR (7.5% vs. 1.6%; p < 0.0001), KMT2A (14.7% vs. 0.2%; p < 0.0001), RUNX1 (22.5% vs. 1.9%; p 0.0001), STAG2 (6.9% vs. 1.6%; p < 0.0001) and TP53 (19.1% vs. 4.1%; p < 0.0001). Conclusions: Mutations linked to therapy targets in AML, such as (FLT3 and IDH1/2), PTPN11, and DNMT3A (both associated with inferior outcomes), are more commonly observed in NPM1mut AML, whereas KMT2A, TP53, and myelodysplastic-related mutations are more commonly observed in NPM1wt AML.

8 January 2022 in Physician Leadership Journal
Verified
Journal Article
Closed access
AGAlexandra Goodman
Alexandra Goodman
FSFathima Keshia Suhail
Fathima Keshia Suhail
DGDevjani Ganesan
Devjani Ganesan
MBMichelle Bernshteyn
Michelle Bernshteyn
ACAlyssa Cortese
Alyssa Cortese
SKStephen Knohl
Stephen Knohl
The American Association for Physician Leadership (AAPL), formerly known as the American College of Physician Executives (ACPE), is the premier organization for online and live CME-earning courses, conferences, and career coaching & services. Learn more about how to earn a CPE credential with us.